Tumorigenesis is the process involved in the production of a new tumor or tumors.
Scientists headed by ICREA researcher Angel R. Nebreda at the Institute for Research in Biomedicine (IRB Barcelona) report a new mechanism that contributes to the development of inflammation-associated colon cancer and points to new therapeutic targets. The study has been published in the journal EMBO Molecular Medicine.
Scientists headed by ICREA researcher Angel R. Nebreda at the Institute for Research in Biomedicine report a new mechanism that contributes to the development of inflammation-associated colon cancer and points to new therapeutic targets
Researchers from Osaka University have discovered how precancerous cells spread to normal tissue and cause cancer.
Testicular germ cell cancer, a disease that is rare but growing in incidence in men in the United States, is considered to be among the most curable of solid tumors. Now researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and a consortium of institutions have discovered the genetic and genomic characteristics that define the disease.
Publication in Nature Cell Biology: researchers at the Université libre de Bruxelles, ULB define for the first time the mechanisms responsible for the mammary gland development.
Cells begin to accumulate centrosomes-;organelles that play a vital role during cell division-;before they transform into cancer cells, according to a new study of patients with Barrett's esophagus condition, which is associated with esophageal cancer.
A recent study has shown that loss of the Erk oncogene can stimulate tumorigenesis in cells where Ras has been eliminated. The findings may have important consequences for the development of personalized medicines that target Ras.
Luxendo, a Bruker company, today announced the extension of the InVi SPIM microscope to include full incubation capabilities, as well as flexible illumination and detection optics.
Tracking the growth and migration of cells under hypoxic conditions in vitro can be challenging because measurements must be made in a manner that does not perturb the atmospheric composition of the closed system.
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development--particularly an epigenetic change involving DNA methylation--arise from rogue cells escaping a natural cell deterioration process called senescence.
Researchers at The Scripps Research Institute recently published a study in the journal Cell Death and Differentiation identifying factors crucial to mesenchymal stem cell differentiation, providing insight into how these cells should be studied for clinical purposes.
Alcohol consumption has been identified as a modifiable risk factor for cancers such as gastric cancer. A new report in the The American Journal of Pathology sheds light on how specific proteins interact with alcohol, and how that interplay impacts survival and response to platinum-based adjuvant chemotherapy in patients with gastric cancer who may or may not still be drinking.
A fusion gene is a single composite gene that is the result of the combination of two formerly independent genes. Researchers from Kumamoto University, Japan have determined that a particular fusion gene has a tendency to be found in cutaneous squamous cell carcinoma (cSCC) lesions on skin exposed frequently to the sun.
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin.
A molecule that controls intestinal cell growth plays a dual role maintaining gut health and promoting diseases such as cancer, says a study in eLife.
The principles of the gene network for colon tumorigenesis have been identified by a KAIST research team. The principles will be used to find the molecular target for effective anti-cancer drugs in the future. Further, this research gained attention for using a systems biology approach, which is an integrated research area of IT and BT.
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs.
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer than any other gene.
Research by Rutgers Cancer Institute of New Jersey investigators shows the targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer carries mutations in the p53 gene.
In an innovative approach to colorectal cancer (CRC) prevention and treatment, scientists are studying ways to replace missing metabolites in patients prone to gut inflammation and CRC.